

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elizabeth M. Denholm, Yong-Qing Lin and Paul J. Silver

Serial No.: Continuation of 09/715,965

Art Unit: Not Yet Assigned

Filed: July 18, 2003

Examiner: Not Yet Assigned

For: *ATTENUATION OF TUMOR GROWTH, METASTASIS AND ANGIOGENESIS*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including five (5) pages of Form PTO-1449. All of the documents cited below were cited by or submitted to the Patent Office in Application Serial No. 09/715,965, filed November 17, 2000, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,696,816	09-29-1987	Brown	424/94
5,567,417	10-22-1996	Sasisekharan et al.	424/94.5
5,945,403	08-31-1999	Folkman et al.	514/21

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
51075042	06-29-1979	Ono Pharm Co. Ltd.	JP
WO 96/01894	01-25-1996	IBEX Technologies	PCT
WO 96/01648	01-25-1996	IBEX Technologies	PCT
WO 96/08559	03-21-1996	Cardiac CRC Nominees PTY, LTD.	

Publications

CRUM, et al., "A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment," *Science* 230(4732): 1375-1378 (1985).

CULP, et al., "Two functionally distinct pools of glycosaminoglycan in the substrate adhesion site of murine cells," *J. Cell Biol.* 79(3):788-801 (1978).

DENHOLM, et al., "The effects of bleomycin on alveolar macrophage growth factor secretion," *Am J Pathol.* 134(2):355-63 (1989).

DENHOLM, et al., "Chondroitinase AC inhibits tumor cell invasion, proliferation, and angiogenesis," *FASEB J* 14(4): A702 (2000).

DENHOLM, et al., "Anti-tumor activities of chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation and invasion," *Eur J Pharmacol* 416(3): 213-221 (20001).

FAASSEN, et. al., "A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion," *J. Cell Biol.* 116(2):521-531 (1992).

FAASSEN, et. al., "Cell surface CD44-related chondroitin sulfate proteoglycan is required for transforming growth factor-beta-stimulated mouse melanoma cell motility and invasive behavior on type I collagen," *J. Cell Science* 105(Pt 2):501-511 (1993).

FOLKMAN, "Angiogenesis in cancer, vascular, rheumatoid and other disease," *Nat Med* 1(1):27-31 (1995).

FOLKMAN, "Successful treatment of an angiogenic disease," *N. Engl. J. Med.* 320(18): 1211-1212 (1989).

FOLKMAN, "Tumor angiogenesis: therapeutic implications," *N. Engl. J. Med.* 285(21): 1182-1186 (1971).

FOLKMAN, et al., "Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone," *Science* 221(4612): 719-725 (1983).

FOLKMAN, et al., "Control of angiogenesis with synthetic heparin substitutes," *Science* 243(4897): 1490-1493 (1989).

FORRESTER, et al., "A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies," *J. Am. Coll. Cardiol.* 17(3):758-769 (1991).

GU, et. al., "Purification, characterization and specificity of chondroitin lyases and glycuronidase from *Flavobacterium heparinum*," *Biochem. J.* 312(Pt 2):569-577 (1995).

HENKE, et. al., "CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix," *J. Clin. Invest.* 97(11):2541-2552 (1996).

INGBER, et al., "*Inhibition of angiogenesis through modulation of collagen metabolism*," *J. Lab. Invest.* 59: 44-51 (1989).

INGBER, et al., "A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution," *Endocrinol.* 119(4): 1768-1775 (1986).

INGBER, et al., "Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix," *J. Cell. Biol.* 109(1): 317-330 (1989).

JACKSON et. al., "Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes," *Physiol. Rev.* 71(2):481-530 (1991).

JIN-INCHI, et al., "Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action," *Cancer Res.* 50:6731-6737 (1990).

LIDA, et al., "Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion," *Sem. Cancer Biol.* 7:155-162, (1996).

LINHARDT, et al., "Polysaccharide lyases," *Appl. Biochem. Biotech.* 12(2): 135-176 (1986).

LINN et. al., "Isolation and characterization of two chondroitin lyases from *Bacteroides thetaiotaomicron*," *J. Bacteriol.* 156(2):859-866 (1983).

MEYER, et al., "Mechanisms of tumour metastasis," *Eur. J. Cancer* 34(2):214-221 (1998).

MICHELACCI, et al., "Isolation and characterization of an induced chondroitinase ABC from *Flavobacterium heparinum*," *Biochim. Biophys. Acta.* 923(2):291-301 (1987).

MURRAY, et al., "Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor," *J. Biol. Chem.* 261(9): 4154-4159 (1986).

NAKAJIMA, et al., "Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines," *Science* 220(4597):611-613 (1983).

RICHARDSON, et al., "Transient morphological and biochemical alterations of arterial proteoglycan during early wound healing," *Exp. Mol. Pathol.* 58(2):77-95 (1993).

SATO, et al., "Submit structure of Chondroitinase ABC from *Proteus vulgaris*," *Agric. Biol. Chem.* 50:1057-1059 (1986).

TABAS, et al., "Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation," *J. Biol. Chem.* 268(27):20419-20432 (1993).

TAKEUCHI, "Effect of chondroitinases on the growth of solid Ehrlich ascites tumour," *Brit J Cancer* 26(2): 115-119 (1972).

TROCHAN, et al., "Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro," *Int. J. Cancer* 66:664-668 (1996).

VOLPI, "Fast moving and slow moving heparins, dermatan sulfate, and chondroitin sulfate: qualitative and quantitative analysis by agarose-gel electrophoresis," *Carbohydrate Res.* 247:263-278 (1993).


YEO, et al., "Alterations in proteoglycan synthesis common to healing wounds and tumors," *Am. J. Pathol.* 138(6):1437-1450 (1991).

ZAWADZKI, et al., "Blockade of metastasis formation by CD44-receptor globulin," *Int. J. Cancer* 75(6):919-924 (1998).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

A handwritten signature in black ink, appearing to be 'Zhaoyang Li', written over a horizontal line.

Zhaoyang Li
Reg. No. 46,872

Dated: July 18, 2003

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com
ATL1 #585894 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete If Known	
				Applicant Number	Continuation 109/715,965
				Filing Date	July 18, 2003
				First Named Inventor	Elizabeth M. Denholm
				Group Art Unit	
				Examiner Name	
Sheet 1 of 5	Attorney Docket Number IT 106 CON				

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
		JP	51075042		Ono Pharm Co. Ltd.	06-29-1979		
		PCT	WO 96/01894		IBEX Technologies	01-25-1996		
		PCT	WO 96/01648		IBEX Technologies	01-25-1996		
		PCT	WO 96/08559		Cardiac CRC Nominees PTY, Ltd.	03-21-1996		

Examine Signature		Date Considered	
-------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete If Known			
				Applicant Number		Continuation of 09/715,965	
				Filing Date		July 18, 2003	
				First Named Inventor		Elizabeth M. Denholm	
				Group Art Unit			
Examiner Name							
Sheet	2	of	5	Attorney Docket Number		IT 106 CON	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		CRUM, et al., "A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment," <i>Science</i> 230(4732): 1375-1378 (1985).	
		CULP, et al., "Two functionally distinct pools of glycosaminoglycan in the substrate adhesion site of murine cells," <i>J. Cell Biol.</i> 79(3):788-801 (1978).	
		DENHOLM, et al., "The effects of bleomycin on alveolar macrophage growth factor secretion," <i>Am J Pathol.</i> 134(2):355-63 (1989).	
		DENHOLM, et al., "Chondroitinase AC inhibits tumor cell invasion, proliferation, and angiogenesis," <i>FASEB J</i> 14(4): A702 (2000).	
		DENHOLM, et al., "Anti-tumor activities of chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation and invasion," <i>Eur J Pharmacol</i> 416(3): 213-221 (2000).	
		FAASSEN, et. al., "A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion," <i>J. Cell Biol.</i> 116(2):521-531 (1992).	
		FAASSEN, et. al., "Cell surface CD44-related chondroitin sulfate proteoglycan is required for transforming growth factor-beta-stimulated mouse melanoma cell motility and invasive behavior on type I collagen," <i>J. Cell Science</i> 105(Pt 2):501-511 (1993).	
		FOLKMAN, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <i>Nat Med</i> 1(1):27-31 (1995).	
		FOLKMAN, "Successful treatment of an angiogenic disease," <i>N. Engl. J. Med.</i> 320(18): 1211-1212 (1989).	
		FOLKMAN, "Tumor angiogenesis: therapeutic implications," <i>N. Engl. J. Med.</i> 285(21): 1182-1186 (1971).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		Continuation of 09/715,965	
				Filing Date		July 18, 2003	
				First Named Inventor		Elizabeth M. Denholm	
				Group Art Unit			
Examiner Name							
Sheet	3	of	5	Attorney Docket Number IT 106 CON			

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		FOLKMAN, et al., "Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone," <i>Science</i> 221(4612): 719-725 (1983).	
		FOLKMAN, et al., "Control of angiogenesis with synthetic heparin substitutes," <i>Science</i> 243(4897): 1490-1493 (1989).	
		FORRESTER, et al., "A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies," <i>J. Am. Coll. Cardiol.</i> 17(3):758-769 (1991).	
		GU, et. al., "Purification, characterization and specificity of chondroitin lyases and glycuronidase from <i>Flavobacterium heparinum</i> ," <i>Biochem. J.</i> 312(Pt 2):569-577 (1995).	
		HENKE, et. al., "CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix," <i>J. Clin. Invest.</i> 97(11):2541-2552 (1996).	
		INGBER, et al., "Inhibition of angiogenesis through modulation of collagen metabolism," <i>J. Lab. Invest.</i> 59: 44-51 (1989).	
		INGBER, et al., "A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution," <i>Endocrinol.</i> 119(4): 1768-1775 (1986).	
		INGBER, et al., "Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix," <i>J. Cell. Biol.</i> 109(1): 317-330 (1989).	
		JACKSON et. al., "Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes," <i>Physiol. Rev.</i> 71(2):481-530 (1991).	
		JIN-INCHI, et al., "Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action," <i>Cancer Res.</i> 50:6731-6737 (1990).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Completeness	
				Application Number	
				Continuation of 09/715,965	
				Filing Date	
				July 18, 2003	
				First Named Inventor	
				Elizabeth M. Denholm	
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	
				IT 106 CON	
Sheet	4	of	5		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		LIDA, et al., "Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion," <i>Sem. Cancer Biol.</i> 7:155-162, (1996).	
		LINHARDT, et al., "Polysaccharide lyases," <i>Appl. Biochem. Biotech.</i> 12(2): 135-176 (1986).	
		LINN et. al., "Isolation and characterization of two chondroitin lyases from <i>Bacteroides thetaiotaomicron</i> ," <i>J. Bacteriol.</i> 156(2):859-866 (1983).	
		MEYER, et al., "Mechanisms of tumour metastasis," <i>Eur. J. Cancer</i> 34(2):214-221 (1998).	
		MICHELACCI, et al., "Isolation and characterization of an induced chondroitinase ABC from <i>Flavobacterium heparinum</i> ," <i>Biochim. Biophys. Acta.</i> 923(2):291-301 (1987).	
		MURRAY, et al., "Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor," <i>J. Biol. Chem.</i> 261(9): 4154-4159 (1986).	
		NAKAJIMA, et al., "Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines," <i>Science</i> 220(4597):611-613 (1983).	
		RICHARDSON, et al., "Transient morphological and biochemical alterations of arterial proteoglycan during early wound healing," <i>Exp. Mol. Pathol.</i> 58(2):77-95 (1993).	
		SATO, et al., "Submit structure of Chondroitinase ABC from <i>Proteus vulgaris</i> ," <i>Agric. Biol. Chem.</i> 50:1057-1059 (1986).	
		TABAS, et al., "Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation," <i>J. Biol. Chem.</i> 268(27):20419-20432 (1993).	

Examiner's Signature		Date Considered	
-----------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known	
		Application Number	Continuation 109/715,965
		Filing Date	July 18, 2003
		First Named Inventor	Elizabeth M. Denholm
		Group Art Unit	
		Examiner Name	
Sheet 5 of 5	Attorney Docket Number	IT 106 CON	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		TAKEUCHI, "Effect of chondroitinases on the growth of solid Ehrlich ascites tumour," <i>Brit J Cancer</i> 26(2): 115-119 (1972).	
		TROCHAN, et al., "Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro," <i>Int. J. Cancer</i> 66:664-668 (1996).	
		VOLPI, "Fast moving and slow moving heparins, dermatan sulfate, and chondroitin sulfate: qualitative and quantitative analysis by agarose-gel electrophoresis," <i>Carbohydrate Res.</i> 247:263-278 (1993).	
		YEO, et al., "Alterations in proteoglycan synthesis common to healing wounds and tumors," <i>Am. J. Pathol.</i> 138(6):1437-1450 (1991).	
		ZAWADZKI, et al., "Blockade of metastasis formation by CD44-receptor globulin," <i>Int. J. Cancer</i> 75(6):919-924 (1998).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.